Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01188811

Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)

Multiple Sclerosis, Chronic Progressive Clinical Trial

Official title:
Lipoic Acid for Neuroprotection in Secondary Progressive MS

Clinical Trial Summary

The purpose of the study is to determine if lipoic acid can protect the brain and slow disability in secondary progressive multiple sclerosis.

Clinical Trial Description

There are no approved medications that are neuroprotective or able to slow disability accumulation in secondary progressive multiple sclerosis (SPMS). This two-year study will determine if daily oral intake of lipoic acid, a natural supplement, will prove superior to placebo in reducing injury to the brain and reducing disability progression in SPMS. Neuroprotection will be measured by the extent of brain volume loss seen on MRI, and disability will be measured by neurological status and quality of life. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01188811
Study type Interventional
Source VA Office of Research and Development
Contact
Status Completed
Phase Phase 2/Phase 3
Start date October 2010
Completion date August 2015
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Recruiting NCT05562414 - Transient and Immediate Motor Effects of Exercise in Progressive Multiple Sclerosis N/A
Completed NCT02545959 - Intrathecal Rituximab in Progressive Multiple Sclerosis Phase 2
Completed NCT01436838 - China Betaferon Adherence, Coping and Nurse Support Study N/A
Completed NCT03799718 - Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS Phase 2
Recruiting NCT00220493 - Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients Phase 1
Recruiting NCT05496881 - Exercise Effects in Multiple Sclerosis N/A
Recruiting NCT02903537 - Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS) Phase 1
Temporarily not available NCT02606929 - Use of Well Known Drugs for New Destination - MS Improvement (MSNT) Phase 0
Completed NCT03424538 - The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients N/A
Completed NCT02403570 - Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis
Active, not recruiting NCT04993274 - Sensitivity of Motor Assessment in MS - a Prospective Cohort Study
Active, not recruiting NCT00411723 - Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis Phase 1
Completed NCT00241254 - Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis Phase 3
Completed NCT02632591 - Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment Phase 1
Not yet recruiting NCT05385731 - MUSCLE - Nordic Walking in MUltiple SCLErosis N/A
Recruiting NCT05359653 - Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy Phase 1/Phase 2
Completed NCT04550650 - Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients N/A
Active, not recruiting NCT03114293 - Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MS N/A